Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR antibody, Vectibix (panitumumab), for treating KRAS G12C-mutated ...

If Amgen can secure full approval for Lumakras ahead of the FDA's 14 December decision date for Mirati's drug, it could close off that route to market and force the company to wait for its own ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Concurrently, their product developments, such as the positive Phase III results for TEZSPIRE® and FDA approval for LUMAKRAS®, signal strong therapeutic advancements. The announcement of Amgen ...

Verastem (NASDAQ:VSTM – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both small-cap medical ...

Amgen 30-Day Option Volume & Interest Snapshot ... Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon ...

Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in ...

Amgen Option Volume And Open Interest Over Last ... Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma).

Amgen’s stock has been rising consistently, with corrections in between due to pipeline setbacks. Amgen’s key medicines, like Evenity and Repatha, newer medicines like Tavneos and Tezspire and ...